Source: International Congress 2019 – New guidelines for treatment of nontuberculous mycobacterial pulmonary disease
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
J. van Ingen (Nijmegen, Netherlands). Advances in the diagnosis of mycobacteria infections and challenges of drug susceptibility testing. International Congress 2019 – New guidelines for treatment of nontuberculous mycobacterial pulmonary disease

Member's Comments

No comment yet.

Related content which might interest you: Use of molecular-genetic methods in diagnostics and therapy of a tuberculosis (TB) at patients with HIV Source: Annual Congress 2010 - Tuberculosis in special populations Year: 2010 The challenges of diagnosing NTM Source: Virtual Congress 2021 – New insights into nontuberculous mycobacteria disease: from diagnosis to treatment Year: 2021 Fate or missed opportunities - challenges in diagnosing paediatric drug resistant tuberculosis in Germany Source: Virtual Congress 2021 – Paediatric respiratory infections: chronic infection, vaccination and lung function Year: 2021 Challenges and perspectives for improved management of HIV/Mycobacterium tuberculosis co-infection Source: Eur Respir J 2010; 36: 1242-1247 Year: 2010 Microbiology of Mycobacterium tuberculosis and a new diagnostic test for TB Source: Eur Respir Mon 2012; 58: 1-13 Year: 2012 Advances in the rapid molecular diagnosis of multidrug- and extensively drug-resistant tuberculosis Source: Annual Congress 2010 - Advances in the diagnosis of tuberculosis and nontuberculous mycobacterial infections: a joint ERS and ATS symposium Year: 2010 Limitations of immune-based diagnostics in patients suspected for pulmonary tuberculosis Source: Annual Congress 2009 - Frontiers in the diagnosis of tuberculosis Year: 2009 The effectiveness of the introduction of the updated treatment regimens and microbiological diagnostics MDR/XDR tuberculosis Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II Year: 2019 Evaluation of new biomarkers for laboratory diagnosis of tuberculosis Source: International Congress 2018 – The immune response to tuberculosis: development of biomarkers and diagnostic tools Year: 2018 The impact and cost-effectiveness of strategies to detect drug-resistant tuberculosis Source: Eur Respir J 2012; 39: 626-634 Year: 2012 IGRA testing to diagnose TB disease and infection. What is new in clinical practice and for programmatic management Source: School Course 2012 - TB and M/XDR-TB: from clinical management to control and elimination Year: 2012 Rapid diagnosis of bacterial co-infection and antimicrobial resistance in patients with SARS-Cov-2 infection Source: Virtual Congress 2021 – Acute COVID - 19 Year: 2021 Modern molecular direct tests for rapid identification and drug susceptibility testing of Mycobacterium tuberculosis Source: Annual Congress 2012 - Microbiological advances in the diagnosis of tuberculosis Year: 2012 Errors in the diagnostics of tuberculosis in children Source: Eur Respir J 2006; 28: Suppl. 50, 23s Year: 2006 CF microbiology, emerging pathogens and more treatment options Source: Annual Congress 2013 –PG20 Cystic fibrosis: an update of the basic defects and clinical problems in CF children and adults Year: 2013 A new era for treatment of drug-resistant tuberculosis Source: Eur Respir J, 52 (4) 1801350; 10.1183/13993003.01350-2018 Year: 2018 Non-tuberculous mycobacterial disease in patients who were referred as MDR-TB in resource limited settings: need for more rapid identification Source: Annual Congress 2008 - Epidemiology and clinical management of multidrug-resistant and extensively drug-resistant tuberculosis Year: 2008 Detecting lung infections in breathprints: empty promise or next generation diagnosis of infections Source: Eur Respir J 2015; 45: 21-24 Year: 2015